Hepion Pharmaceuticals Inc (NASDAQ:HEPA)
| 9.62 Delayed Data As of May 31 |  -1.07 / -10.01%Today’s Change | 5.20 Today|||52-Week Range 23.85 | +60.17% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $42.1M |
Company Description
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.
Contact Information
Hepion Pharmaceuticals, Inc. 399 Thornall Street Edison New Jersey 08837 |
Employees
Shareholders
| Mutual fund holders | -- |
| Individual stakeholders | -- |
| Other institutional | -- |
Top Executives
| Robert T. Foster | President, Chief Executive Officer & Director |
| Launa J. Aspeslet | Chief Operating Officer |
| John T. Cavan | Chief Financial Officer |
| Daren Ure | Chief Scientific Officer |
| Todd Milton Hobbs | Chief Medical Officer |
